{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.1","value":"80.0"},{"groupId":"OG001","spread":"28.4","value":"71.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Plasma samples for pharmacokinetic (PK) analysis of GSK3529246 (active metabolite) were collected at the indicated time points. GSK3529246 is a metabolite of GSK525762. Pharmacokinetic parameters were calculated by empirical Bayes estimates. GSK3529246 plasma concentration-time data was analyzed by Population PK methods using a non-linear mixed-effects modelling approach.","dispersionType":"Standard Deviation","groups":[{"description":"Participants Cutaneous T cell lymphoma (CTCL) were administered once daily oral dose of 60 mg GSK525762.","id":"OG000","title":"Part 2: GSK525762 60 mg QD CTCL"},{"description":"Participants with Myelodysplastic Syndrome (MDS) were administered once daily oral dose of 75 mg GSK525762","id":"OG001","title":"Part 2: GSK525762 75 mg QD MDS"},{"description":"Participants CTCL were administered once daily oral dose of 80 mg GSK525762","id":"OG002","title":"Part 2: GSK525762 80 mg QD CTCL"}],"paramType":"MEAN","populationDescription":"PK Population. Given only one participant at 80 mg for single dose data, population PK analysis of combined data from 75 mg QD and 80 mg QD CTCL was more appropriate. Hence the single participant of 80 mg QD arm was included in 75 mg QD MDS arm which leads to \"N\" of 75 mg arm within this outcome measure is greater than overall \"N\" for 75 mg QD MDS \\& N=0 for 80 mg QD CTCL.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1: pre-dose and at 0.5 - 2 hours, 4 - 8 hours post-dose","title":"Part 2: Apparent Central Volume of Distribution (V1/F) of GSK3529246 (Active Metabolite) Following Single Dose Administration","type":"SECONDARY","unitOfMeasure":"Liters"}